Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23775560

DOI
10.1002/cncr.28196

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Algorithms; Antibodies, Monoclonal, Humanized /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Biomarkers, Tumor /metabolism; Breast Neoplasms /drug therapy /economics /metabolism /pathology; Cost-Benefit Analysis; Decision Support Techniques; False Negative Reactions; Female; Health Care Costs; Humans; Immunohistochemistry /economics; In Situ Hybridization, Fluorescence /economics; Middle Aged; Neoplasm Staging; Patient Acceptance of Health Care; Quality-Adjusted Life Years; Receptor, ErbB-2 /metabolism; Sensitivity and Specificity; Trastuzumab; United States

AccessionNumber
22013025080

Date bibliographic record published
09/07/2013